Dissecting the Drug and Device Industries’ Leading Legal Cases Preparing Your Legal and Regulatory Affairs Teams for 2011

Held March 30, 2011

It already appears that 2011 will be a watershed year for legal actions affecting drug, device and biologics manufacturers.

In fact, there have been so many important court rulings that your legal, regulatory affairs and compliance teams may be hard pressed to stay on top of them all.

Don’t put yourself at a dangerous disadvantage.

Instead, attend this webinar, featuring a top attorney who’ll bring you up to date on these major court cases and what they will mean for your business in 2011.

No matter how quickly the courts redefine and reinterpret complex rules, you can be sure that the FDA will expect your legal, regulatory and compliance team to keep you on top of the changes — and in compliance with what’s required.

With so much at stake, why not avoid the risk of noncompliance by registering for this timely FDAnews webinar?

In just 90 minutes, Alan Minsk, Partner at Arnall Golden Gregory, will define and address the compliance issues that will arise in 2011 from these specific cases:

  • Smith v. Bayer
  • Mattrix Initiatives v. Siracusano
  • Pliva v. Mensing
  • Sorrell v. IMS
  • Bruesewitz v. Wyeth

Register now for Dissecting the Drug and Device Industries’ Leading Legal Cases and you’ll get expert guidance on:

  • The issues surrounding the cases, potential risks and specific concerns for drug, device and biologics makers as well as research organizations
  • How legal action is likely to affect Federal preemption in 2011 and beyond
  • How a Supreme Court case involving securities law could change drug and device adverse event reporting
  • Best practices for protecting your company from the rising tide of class-action claims
  • And more

A flexible fit for your busy schedule

The webinar is convenient to attend. All that’s required is that you be in front of a screen at the appointed time, whether at the office or telecommuting from an office-in-home.

Of course, Alan Minsk will be on hand to answer all of your questions. Simply submit your questions via email, and you’ll have answers by the time the session ends.

Key people on your legal, regulatory affairs and compliance teams will benefit from attending Dissecting the Drug and Device Industries’ Leading Legal Cases. Best of all, everyone can do so at a cost that won’t break the budget. You pay one single low registration fee per facility, regardless of how many participate. So spread the word to your entire team!

This webinar is offers valuable early-warning legal perspective to executives and personnel in medical device, pharmaceutical and biologics companies; CRO; and academic research organizations, including:

  • Regulatory Affairs Personnel
  • Compliance Officials
  • Lawyers

Phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Alan Minsk is a Partner and Chair of the Food & Drug Practice Team of Arnall Golden Gregory LLP. He advises pharmaceutical and medical device companies on all legal and regulatory matters relating to the FDA, and certain matters concerning numerous other governmental agencies.

He counsels, speaks and writes on a wide variety of FDA-related issues, including product promotion and advertising, FDA enforcement, regulatory strategy and lifecycle management, market exclusivity, FDA inspections, corporate compliance, regulation of dietary supplements, product liability, imports and exports, and clinical trial issues. He also conducts in-house training on a wide variety of FDA and fraud and abuse-related topics.

He is also a past Leader of the RAPS Georgia Chapter, and is a member of numerous industry and legal associations. He earned his J.D. from the Georgetown University Law Center.

Order now!